Persistent psychotic symptoms after long-term heavy use of mephedrone: A two-case series

Authors

  • Pablo Barrio Centro para la Investigación y el Tratamiento de las Adicciones, Dosrius, Barcelona Addictive Behaviors Unit, Clinical Neuroscience Institute, Clinic Hospital, Barcelona
  • Matthew Gaskell Leeds Addiction Unit, 19 Springfield Mount, Leeds, LS2 9NG, UK.
  • Javier Goti Centro para la Investigación y el Tratamiento de las Adicciones, Dosrius, Barcelona Department of Child and Adolescent Psychiatry and Psychology, Institute Clinic of Neurosciences, Hospital Clínic Universitari, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)
  • Sergi Vilardell Centro para la Investigación y el Tratamiento de las Adicciones, Dosrius, Barcelona
  • Josep Maria Fàbregas Centro para la Investigación y el Tratamiento de las Adicciones, Dosrius, Barcelona

DOI:

https://doi.org/10.20882/adicciones.824

Keywords:

mephedrone, cathinone, drug dependence, psychosis, heavy use, new psychoactibe substances.

Abstract

Mephedrone (4-methylmethcathinone) is a synthetic stimulant drug of the cathinone class. Similar effects to those of cocaine and ecstasy are reported by users, with a high addictive potential. Given its increasing rate of consumption in Europe, it is getting more and more attention from the addiction field. In spite of that, little is known about the long-term consequences of prolonged heavy use. The two following cases might depict some of them. Case 1 was a middle-age man who reported three years of intravenous use of mephedrone. He used to binge for several days in a row. Psychotic symptoms appeared after a few months, especially paranoid delusions. Sent to aftercare in a therapeutic community, delusions kept reappearing after prolonged abstinence. A good response to risperidone was observed. Case 2 was a young man who used mephedrone heavily for two years, always snorted. Upon admission to the therapeutic community, the patient reported auditory hallucinations that partially remitted with olanzapine. Both cases showed a good insight and no personality deterioration. Given its similarities to other substances that are known to induce psychotic symptoms, and the increasing consumption of mephedrone around Europe, similar cases are expected in the near future. Conventional antipsychotic treatment seems a reasonable pharmacological approach.

References

Bajaj, N., Mullen, D. & Wylie, S. (2010). Dependence and psychosis with 4-methylmethcathinone (mephedrone) use. BMJ Case Reports, 2010. doi:10.1136/bcr.02.2010.2780

Bramness, J. G., Gundersen, Ø. H., Guterstam, J., Rognli, E. B., Konstenius, M., Løberg, E.-M., … Franck, J. (2012). Amphetamine-induced psychosis--a separate diagnostic entity or primary psychosis triggered in the vulnerable? BMC Psychiatry, 12, 221. doi:10.1186/1471-244X-12-221

Dragogna, F., Oldani, L., Buoli, M. & Altamura, A. C. (2014). A case of severe psychosis induced by novel recreational drugs. F1000Research, 3, 21. doi:10.12688/f1000research.3-21.v1

European Center for Monitoring Drugs and Drug Addiction (2010). Europol–EMCDDA Joint Report on a new psychoactive substance: 4-methylmethcathinone (mephedrone).

Gregg, R. A. & Rawls, S. M. (2014). Behavioral pharmacology of designer cathinones: a review of the preclinical literature. Life Sciences, 97, 27–30. doi:10.1016/j.lfs.2013.10.033

Lichlyter, B., Purdon, S. & Tibbo, P. (2011). Predictors of psychosis severity in individuals with primary stimulant addictions. Addictive Behaviors, 36, 137–9. doi:10.1016/j.addbeh.2010.08.019

Martínez-Clemente, J., López-Arnau, R., Abad, S., Pubill, D., Escubedo, E. & Camarasa, J. (2014). Dose and time-dependent selective neurotoxicity induced by mephedrone in mice. PloS One, 9, e99002. doi:10.1371/journal.pone.0099002

Nogué, S., Amigó, M. & Galicia, M. (2014). Raves, consumo de drogas y asistencia en urgencias. Adicciones, 26, 189–190. Retrieved from http://www.redalyc.org/articulo.oa?id=289131590012

Weaver, M. F., Hopper, J. A. & Gunderson, E. W. (2015). Designer drugs 2015: assessment and management. Addiction Science & Clinical Practice, 10, 8. doi:10.1186/s13722-015-0024-7

Winstock, A. R., Mitcheson, L. R., Deluca, P., Davey, Z., Corazza, O. & Schifano, F. (2011). Mephedrone, new kid for the chop? Addiction, 106, 154–61. doi:10.1111/j.1360-0443.2010.03130.x

Published

2016-06-15

Issue

Section

Originals